Home application review
 

Keywords :   


Tag: application review

Citizen Review Committee volunteer application

2014-10-09 03:05:24| PortlandOnline

City Auditors Independent Police Review is accepting applications to serve on the Citizen Review Committee

Tags: review application committee volunteer

 

Land Use Review Application Narrative

2014-09-29 23:29:27| PortlandOnline

Submitted: September 26, 2014 PDF Document, 9,626kbCategory: Initial Submittal of Land Use Review Application$

Tags: review land application narrative

 
 

Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

2014-09-03 12:22:48| drugdiscoveryonline Home Page

Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds

Tags: review application license acceptance

 

Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma

2014-05-06 14:40:00| Merck.com - Corporate News

Dateline City: BOSTON Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting Initiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166) BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Mercks investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced review application license

 

FDA Accepts for Review Mercks Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine

2014-02-20 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration. About Merck Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application human license

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] next »